The main risk is sequencing, not product relevance. Stem likely has enough real software and control value to matter, but the company must translate bookings into revenue, expand recurring software, and protect liquidity at the same time. If that sequence slips,
dilution or defensive financing can absorb much of the upside before the business earns a cleaner
rerating.